Abera Bioscience nasal pneumococcal vaccine Ab — 01.12 advances toward Phase 1 trial in Netherlands
Abera Bioscience AB reported a new npj Vaccines paper summarizing preclinical work supporting its intranasal pneumococcal vaccine candidate Ab-01.12. Results were already presented in the publication; human safety and immune response data will be generated in a planned Phase 1 trial. Animal studies showed the candidate